Represented Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in the execution of license and supply agreements in connection with its strategic partnership with Servier Canada, Inc. for the out-license of commercialization rights to ZEVALIN®, FOLOTYN®, BELEODAQ®, and MARQIBO® in Canada.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with expanding its global license and supply agreements with SAGE Therapeutics. The agreement now covers the use of Captisol in the development and commercialization of SAGE-689.
Secured favorable settlement on behalf of defendant Specialty Enzymes and Biotechnologies in a dispute over indemnities related to alleged contamination in a consumer product. *
Represented Ligand Pharmaceuticals Incorporated in connection with a global license and supply agreement with Sanofi to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its acquisition of a portfolio of milestone and royalty payments of more than 15 biologic development programs from Selexis SA for $4 million in cash. Ligand also previously acquired a separate portfolio of more than 15 programs from Selexis in 2013.
Represented Allegro Ophthalmics, LLC in its transaction with Hanmi Pharmaceutical Co., Ltd. which includes license of certain Asian rights to Hanmi, and a $20 million strategic investment by Hanmi in Allegro. Allegro develops novel integrin peptide therapies for the treatment of vitreoretinal diseases.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in expanding its global license agreement with CURx Pharmaceuticals, Inc. The agreement now includes the development and commercialization of Ligand’s Captisol-enabled Lamotrigine program. According to the terms of the expanded license, Ligand is eligible to receive $22 million in milestone payments.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its signing of a commercial license agreement for the development and commercialization for four Captisol-enabled programs with Avion Pharmaceuticals, LLC. Pursuant to the agreement, Ligand will receive an up-front payment and is also eligible to receive revenue from Captisol material sales, milestone payments, and royalties on future net sales.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its signing of an exclusive global license agreement with TG Therapeutics, Inc. (NASDAQ: TGTX) for Ligand’s Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. Under the terms of the license, Ligand is eligible to receive $207 million in milestone payments.
Represented Spectrum Pharmaceuticals (NASDAQ: SPPI) in its Rule 144A offering of $120 million aggregate principal amount of its 2.75% convertible senior notes due 2018.
Represented Evolus, Inc. in its acquisition by Strathspey Crown Holdings LLC. Read the press release.
Represented Evolus, Inc., a U.S. biotech venture, in its exclusive licensing deal with Daewoong Pharmaceutical Co., a major South Korean drugmaker, in Daewoong's bid to sell its botox products in the U.S. and European markets beginning as early as 2016.
Represented Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) in its $12 million private placement. The proceeds will be used for product research, aquaculture and Keyhole Limpet Hemocyanin (KLH) production development, capital expenditures and working capital. Read the press release.
Represented Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) in its acquisition of Talon Therapeutics, Inc. (OTCQB: TLON), a biopharmaceutical company based in South San Francisco, California. The deal includes upfront payments of approximately $45 million in cash and stock, and future earn-outs of up to $195 million.
Represented Allegro Ophthalmics, LLC in a licensing deal with Senju Pharmaceutical Co., Ltd. to develop and market Allegro's Integrin Peptide Therapy in Japan. Read the press release.
Represented Ligand Pharmaceuticals Incorporated in its purchase of $4.5 million of royalty and milestone payment rights from Selexis SA.
Conducted audit of company compliance policies and provided recommendations and counseling to improve compliance program.